

## Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of the groups n = 5

## EQA round: BIL2/22 - Bilirubin Neonatal

Deadline: 26.08.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(215) Bilirubin total</b>					125							125	118	94%
--- Samples and groups ---	[µmol/L]													
<b>Sample A</b>		225	15	6,8	125	CVP	225	3,4	20%	180	270	125	122	98%
(1) Abbott		225	7,8	3,5	20							20		
(58) Beckman Coulter (AU)		235	3,5	1,5	20							20		
(60) Roche		213	7,4	3,5	51							51		
(149) Siemens (Dade, BN, Dimension)		232	1,70,73		5							5		
(162) Siemens (Atellica)		241	15	6,1	8							8		
(179) Siemens		238	14	5,9	10							10		
Other					11							11		
						2x 12, 1x 40, 2x 46, 2x 49, 1x 61, 1x 70, 1x 77, 1x 158								
<b>Sample B</b>		366	26	7,1	125	CVP	366	5,7	20%	292	440	125	119	95%
(1) Abbott		379	13	3,5	20							20		
(58) Beckman Coulter (AU)		357	9,8	2,7	20							20		
(60) Roche		348	12	3,6	51							51		
(149) Siemens (Dade, BN, Dimension)		379	5,8	1,5	5							5		
(162) Siemens (Atellica)		404	23	5,7	8							8		
(179) Siemens		398	27	6,8	10							10		
Other					11							11		
						2x 12, 1x 40, 2x 46, 2x 49, 1x 61, 1x 70, 1x 77, 1x 158								

st\_kn\_p

End of report

Printed: 29.08.2022